Philip Masson

Philip Masson

Auto-generated profile, based on publicly available information

Philip Masson

Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2021 in BMJ
Verified
Journal Article
Open access
PDF file
NMNicole L De La Mata
Nicole L De La Mata
BRBrenda Rosales
Brenda Rosales
GMGrace MacLeod
Grace MacLeod
PKPatrick J Kelly
Patrick J Kelly
PMPhilip Masson
Philip Masson
AWAngela C Webster
Angela C Webster
Objective To evaluate sex differences in mortality among people with kidney failure compared with the general population. Design Population based cohort study using data linkage. Setting The Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), which includes all patients receiving kidney replacement therapy in Australia (1980-2019) and New Zealand (1988-2019). Data were linked to national death registers to determine deaths and their causes, with additional details obtained from ANZDATA. Participants Of 82 844 people with kidney failure, 33 329 were female (40%) and 49 555 were male (60%); 49 376 deaths (20 099 in female patients; 29 277 in male patients) were recorded over a total of 536 602 person years of follow-up. Main outcome measures Relative measures of survival, including standardised mortality ratios, relative survival, and years of life lost, using general population data to account for background mortality (adjusting for country, age, sex, and year). Estimates were stratified by dialysis modality (haemodialysis or peritoneal dialysis) and for the subpopulation of kidney transplant recipients. Results Few differences in outcomes were found between male and female patients with kidney failure. However, compared with the general population, female patients with kidney failure had greater excess all cause deaths than male patients (female patients: standardised mortality ratio 11.3, 95% confidence interval 11.2 to 11.5, expected deaths 1781, observed deaths 20 099; male patients: 6.9, 6.8 to 6.9, expected deaths 4272, observed deaths 29 277). The greatest difference was observed among younger patients and those who died from cardiovascular disease. Relative survival was also consistently lower in female patients, with adjusted excess mortality 11% higher (95% confidence interval 8% to 13%). Average years of life lost was 3.6 years (95% confidence interval 3.6 to 3.7) greater in female patients with kidney failure compared with male patients across all ages. No major differences were found in mortality by sex for haemodialysis or peritoneal dialysis. Kidney transplantation reduced but did not entirely remove the sex difference in excess mortality, with similar relative survival (P=0.83) and years of life lost difference reduced to 2.3 years (95% confidence interval 2.2 to 2.3) between female and male patients. Conclusions Compared with the general population, female patients had greater excess deaths, worse relative survival, and more years of life lost than male patients, however kidney transplantation reduced these differences. Future research should investigate whether systematic differences exist in access to care and possible strategies to mitigate excess mortality among female patients.

1 January 2020 in Eating Behaviors
Verified
Journal Article
Closed access
AKAaron Keshen
Aaron Keshen
THThomas Helson
Thomas Helson
SASarrah Ali
Sarrah Ali
LDLaura Dixon
Laura Dixon
IIIryna Ivanova
Iryna Ivanova
JTJoel Town
Joel Town

21 May 2015 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
PMPhilip Masson
Philip Masson
SKSradha Kotwal
Sradha Kotwal
PKPatrick J Kelly
Patrick J Kelly
JCJonathan C Craig
Jonathan C Craig
RLRichard I Lindley
Richard I Lindley
AWAngela C Webster
Angela C Webster
Introduction and Aims: To determine the effects of traditional cardiovascular risks factors and identify novel risk factors for stroke in people with end-stage kidney disease (ESKD).